Nearly 30 years after the advent of antiretroviral therapy (ART), CNS opportunistic infections
remain a major cause of morbidity and mortality in HIV-positive individuals. Unknown HIV …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …

Progressive multifocal leukoencephalopathy (PML) is a rare, devastating demyelinating
disease of the CNS caused by the JC virus (JCV) that occurs in patients with compromised …

In 1997, rituximab was the first monoclonal antibody clinically approved for the treatment of
cancer. Ten years later, progressive multifocal leukoencephalopathy (PML), until that time a …

Progressive multifocal leukoencephalopathy (PML) associated with natalizumab treatment
continues to be a severe problem of clinically successful therapy. This is an update of risk …

Cases of PML should be evaluated according to predisposing factors, as these subgroups
differ by incidence rate, clinical course, and prognosis. The three most significant groups at …

Progressive multifocal leukoencephalopathy (PML) is a serious and usually fatal CNS
infection caused by the John Cunningham virus. CD4+ and CD8+ T-cell lymphopenia …

Objective: To identify and summarize FDA's Adverse Event Reporting System (FAERS)
cases of progressive multifocal leukoencephalopathy (PML) associated with biological and …

Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal condition
caused by a brain infection with JC polyomavirus (JCV). PML develops almost exclusively in …

Natalizumab, a highly effective therapy for relapsing-remitting multiple sclerosis, is
associated with a risk of progressive multifocal leukoencephalopathy (PML). The objective of …